# Stoke Therapeutics, Inc. (STOK)

> Source: Nexqual · https://nexqual.com/STOK · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Stoke Therapeutics, Inc. (STOK), nexqual.com/STOK" · informational, not investment advice.

**Price:** USD 25.7 (+0.08% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 25.68 · day 25.64–26.7 · 52w 20.32–40.22 · market cap $1.66B · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $27.6M, net income -$208M (-753.6% margin), free cash flow -$181M (SEC filings).
- Insider open-market sales, last ~7 months: 11 Form 4 filings, $1.5M; 3 not under a Rule 10b5-1 plan ($647K); 3 by opportunistic insiders (1 outside 10b5-1 plans), 7 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.86 on a 1–5 scale) (14 analysts), mean target USD 46.46 (range 35–60).
- Total return with dividends: 1Y -18.9% vs S&P 500 +14.9%; 5Y +5.8% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD -0.91, revenue estimate $8.2M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | $12.4M | $8.8M | $36.6M | $184M | $27.6M |
| Operating income | -$86.1M | -$104M | -$115M | -$101M | -$20.6M | -$223M |
| Net income | -$85.8M | -$101M | -$105M | -$89.0M | -$6.9M | -$208M |
| EPS (diluted) | -$2.34 | -$2.60 | -$2.38 | -$1.65 | -$0.12 | — |
| Free cash flow | -$68.1M | -$35.8M | -$82.7M | -$87.1M | $44.9M | -$181M |
| Operating margin | — | -841.2% | -1307.2% | -277.3% | -11.2% | -809.7% |
| Net margin | — | -814.7% | -1192.5% | -243.4% | -3.7% | -753.6% |
| Revenue growth | — | — | -29.2% | +316.3% | +404.5% | — |
| Cash + short-term investments | $220M | $230M | $201M | $217M | $285M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 60.1x · P/B 4.8x · FCF yield -10.90% · Earnings yield -12.54%

## Insider sales (SEC Form 4, open-market, last ~7 months)
8 of 11 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 627 | $17K | 3% | Yes (adopted November 10, 2025) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-10-01 | Ticho Barry | CHIEF MEDICAL OFFICER | 1,051 | $27K | 5.2% | Yes (adopted November 19, 2025) | Routine (sold in May & Jun & Jul each year 2023–2025; this trade is outside those months) |
| 2026-09-01 | Ticho Barry | CHIEF MEDICAL OFFICER | 5,545 | $170K | 21.6% | Yes (adopted November 19, 2025) | Routine (sold in May & Jun & Jul each year 2023–2025; this trade is outside those months) |
| 2026-08-18 | Ticho Barry | CHIEF MEDICAL OFFICER | 4,767 | $153K | 15.7% | No | Routine (sold in May & Jun & Jul each year 2023–2025; this trade is outside those months) |
| 2026-08-18 | Kaye Edward M. Md | Director | 12,567 | $403K | 9.2% | No | Too little history (no open-market trades in 2023) |
| 2026-08-18 | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 2,861 | $92K | 11.9% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-08-03 | Ticho Barry | CHIEF MEDICAL OFFICER | 7,176 | $208K | 26% | Yes (adopted November 19, 2025) | Routine (sold in May & Jun & Jul each year 2023–2025; this trade is outside those months) |
| 2026-07-01 | Ticho Barry | CHIEF MEDICAL OFFICER | 7,228 | $236K | 20.8% | Yes (adopted November 19, 2025) | Routine (sold in May & Jun & Jul each year 2023–2025) |
| 2026-06-16 | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 1,457 | $44K | 7.5% | Yes (adopted November 10, 2025) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-06-01 | Ticho Barry | CHIEF MEDICAL OFFICER | 1,795 | $55K | 4.9% | Yes (adopted November 19, 2025) | Routine (sold in May & Jun & Jul each year 2023–2025) |
| 2026-05-01 | Ticho Barry | CHIEF MEDICAL OFFICER | 2,243 | $74K | 5.8% | Yes (adopted November 19, 2025) | Routine (sold in May & Jun & Jul each year 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 1.86 on a 1–5 scale), 14 analysts; mean target USD 46.46 (low 35, high 60).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-04 | Guggenheim | Reiterated | Buy | $60 |
| 2026-08-04 | Wedbush | Target raised | Outperform | $38 → $40 |
| 2026-08-04 | Canaccord Genuity | Target lowered | Buy | $60 → $58 |
| 2026-08-04 | Chardan Capital | Maintained | Buy | $35 |
| 2026-07-13 | Goldman Sachs | Initiated | Buy | $44 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -18.9% | +5.8% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -19.0% | +1.1% |
| Volatility (annualized) | 57.0% | 83.2% |
| Max drawdown | -41.3% (Mar 2026→Oct 2026) | -88.1% (Nov 2021→Oct 2023) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/STOK · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name STOK in their own reports (relationship from STOK's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | ACADIA PHARMACEUTICALS INC (ACAD) | 10-K 2026-02-26 | "In January 2022, we entered into a license and collaboration with Stoke Therapeutics, Inc. (Stoke) to discover, develop and commercialize novel RNA-based medicines for the potential treatment of sever…" |

## Company outlook (8-K filed 2026-08-03)

- "EX-99.1 2 stok-ex99_1.htm EX-99.1 EX-99.1 EX 99.1 Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates – Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data readout anticipated in Q3 2027– – Pre-NDA meeting with FDA scheduled for H2 2026; rolling U.S."
- "With the June 2026 completion of enrollment of 162 patients into EMPEROR, a Phase 3 readout is anticipated in the third quarter of 2027."
- "Safety and efficacy data are anticipated in the first half of 2027. "We have made significant progress across our business this year, including the rapid enrollment of 162 patients into the Phase 3 EMPEROR study and progression of these patients through key study milestones with the first patients now approaching the end of the 52-week treatment period," said Ian F."
- "Dose escalation continues in our Phase 1 study of STK-002 in patients with ADOA and initial data are anticipated in the first half of 2027 to guide future clinical development."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.91 | $-0.81 | +12.6% | $8.2M | 12 |
| Next quarter (ends 2026-12-31) | $-0.97 | $-0.88 | +10.8% | $8.2M | 12 |
| Current fiscal year (ends 2026-12-31) | $-3.62 | $-3.25 | +11.6% | $32.0M | 12 |
| Next fiscal year (ends 2027-12-31) | $-3.53 | $-3.08 | +14.4% | $44.8M | 12 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-10-29): ±17.6%; last 8 reports averaged ±9.4%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 79.6% | ±17.6% |
| 2027-02-19 | 119 | 59.4% | ±26.7% |
| 2027-05-21 | 210 | 61.6% | ±36.4% |